Meanwhile, MEK1/2 was considered to be the most suitable target for early tumor suppression, but the prevalent resistance to MEK inhibitors makes MEK1/2 not a suitable target for tumor treatment [58]. The gene discussed is MAP2K1; the disease is neoplasm.